Your browser doesn't support javascript.
loading
EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer.
Yamaguchi, H; Du, Y; Nakai, K; Ding, M; Chang, S-S; Hsu, J L; Yao, J; Wei, Y; Nie, L; Jiao, S; Chang, W-C; Chen, C-H; Yu, Y; Hortobagyi, G N; Hung, M-C.
  • Yamaguchi H; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Du Y; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Nakai K; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Ding M; Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX, USA.
  • Chang SS; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Hsu JL; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Yao J; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Wei Y; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Nie L; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Jiao S; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Chang WC; Genomics Research Center, Academia Sinica, Taipei, Taiwan.
  • Chen CH; Graduate Institute of Biomedical Sciences and Center for Molecular Medicine, China Medical University, Taichung, Taiwan.
  • Yu Y; Genomics Research Center, Academia Sinica, Taipei, Taiwan.
  • Hortobagyi GN; Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX, USA.
  • Hung MC; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Oncogene ; 37(2): 208-217, 2018 01 11.
Article en En | MEDLINE | ID: mdl-28925391
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Neoplasias de la Mama / Resistencia a Antineoplásicos / Inhibidores de Poli(ADP-Ribosa) Polimerasas / Proteína Potenciadora del Homólogo Zeste 2 / Poli(ADP-Ribosa) Polimerasa-1 Límite: Animals / Female / Humans Idioma: En Año: 2018 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Neoplasias de la Mama / Resistencia a Antineoplásicos / Inhibidores de Poli(ADP-Ribosa) Polimerasas / Proteína Potenciadora del Homólogo Zeste 2 / Poli(ADP-Ribosa) Polimerasa-1 Límite: Animals / Female / Humans Idioma: En Año: 2018 Tipo del documento: Article